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Abstract
Machine learning offers great opportunities to streamline and improve clinical care from the perspective of cardiac imagers,
patients, and the industry and is a very active scientific research field. In light of these advances, the European Society of
Cardiovascular Radiology (ESCR), a non-profit medical society dedicated to advancing cardiovascular radiology, has assembled
a position statement regarding the use of machine learning (ML) in cardiovascular imaging. The purpose of this statement is to
provide guidance on requirements for successful development and implementation of ML applications in cardiovascular imag-
ing. In particular, recommendations on how to adequately design ML studies and how to report and interpret their results are
provided. Finally, we identify opportunities and challenges ahead. While the focus of this position statement is ML development
in cardiovascular imaging, most considerations are relevant to ML in radiology in general.
Key Points
• Development and clinical implementation of machine learning in cardiovascular imaging is a multidisciplinary pursuit.
• Based on existing study quality standard frameworks such as SPIRIT and STARD, we propose a list of quality criteria for ML
studies in radiology.
• The cardiovascular imaging research community should strive for the compilation of multicenter datasets for the development,
evaluation, and benchmarking of ML algorithms.
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Introduction
Artificial intelligence (AI), machine learning (ML), and deep
learning (DL) are currently getting a lot of attention in the public
arena and in science [1]. Their relation is hierarchically nested as
shown in Fig. 1. AI is an umbrella term encompassing all tech-
niques that mimic human intelligence, which have been studied
and applied for decades [2], whereasML describes a subset of AI
algorithms that learn to map input parameters to output from
training data (supervised ML) or identify previously undetected
patterns (unsupervisedML). DL comprises a subset of ML algo-
rithms that use multiple, connected calculation layers [3].
Open source programming tools, as well as greater compu-
tational power and easier data transfer facilitate the current
boost in availability and productivity of AI algorithms.
Concretely, in the most prevalent case of supervised ML,
multiple pairs of input (e.g., MR image data of the heart)
and output (e.g., ground truth segmentation of the left ventri-
cle [LV]) are used for training. Subsequently, the trained al-
gorithm can be used to automatically solve the learned task
upon presentation of new, unseen input data. The fundamen-
tals of ML have been described extensively elsewhere [4–6].
ML algorithms are of special interest to radiologists, be-
cause main areas of application are image processing, image
analysis, and detection of findings—all core components of
the radiological workflow before interpretation. One of their
strengths is image segmentation, which is a prerequisite for
analyses such as calculation of cardiac stroke volumes.
Consequently, an increasing number of ML algorithms have
been designed and evaluated in the field of cardiovascular
radiology. Segmentation tasks are predominantly solved with
DL algorithms, which have shown performances superior to
traditional image processing methods. However, applications
of ML extend beyond image analysis and can support many
other tasks within the field of radiology such as triage of
exams according to urgency or provision of a second reading
to avoid missing relevant findings. They can also help with
predicting outcomes and extending the diagnostic capabilities
of CT and MRI, e.g., by assessing the fractional flow reserve
from cardiac CT angiography.
In light of these advances, the European Society of
Cardiovascular Radiology (ESCR), a non-profit medical soci-
ety dedicated to advancing cardiovascular radiology, has as-
sembled a position statement regarding the use of ML in car-
diovascular imaging in close cooperation with other leading
societies in the field.While the focus of this position statement
is ML development in cardiovascular imaging, most consid-
erations are relevant to ML in radiology in general.
Requirements for successful development
and implementation of ML algorithms
in radiology
(a) Human resources and expertise
Consensus statement
• Machine learning projects in cardiovascular imaging
should involve experts with different professional back-
grounds,mainlymedical andMLexperts, and in later stages
also experts in user interface design and regulatory matters.
• The research and business community should agree on com-
mon data format standards and easy export of segmentation
masks from clinically used post-processing software is need-
ed to foster data interchangeability and reusability of data.
• Integration of ML algorithms into existing clinical
workflows should be smooth, preferably into primary
systems (RIS/PACS), to assure utility and acceptance by
users.
A successful ML project in radiology is almost always
multidisciplinary. It can be seen as a four-step process, each
step requiring special expertise and ideally a close cooperation
between multiple professionals, mainly medical and ML
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experts. This section describes human resources required for a
successful ML project as well as key activities at each of the
four steps.
The initial, crucial question is what problem to solve. For
this, one needs clinical domain knowledge to identify a rele-
vant problem. On the other hand, knowledge in programming
is needed to assess whether the identified clinical problem is
technically solvable by means of ML. Furthermore, one
should always ask whether ML is the best solution for the
problem or if there are other, less complex solutions, such as
a manual workflow in the case of rarely occurring tasks. Apart
fromML, there are many traditional imaging processing tech-
niques like region growing that are very effective for e.g.
tracing the coronary arteries [7]. To clarify these issues, a
close cooperation between clinical experts and computer sci-
entists is necessary. Furthermore, patients’ interests should be
considered at this stage.
Once a relevant clinical problem best solved by means of
ML is identified, the second step is algorithm development. In
the predominant case of supervised learning, this starts with
data selection and establishment of ground truth. Obtaining a
sufficient amount of high-quality ground truth data, which can
be thought of as “gold standard” used for both ML training and
evaluation (e.g., segmentation masks of the left ventricle) is a
necessary requirement for creating an algorithm. The amount of
data needed depends on the complexity of the problem, theML
algorithm used, and the ratio between the finding of interest and
the whole dataset. As a rule of thumb and providing an example
from the field of object detection, tasks that are easy to solve for
a human reader (e.g., detection and segmentation of a healthy
lung within a chest CT scan) will require less training data than
the detection of subtle, small changes in a whole-body CT scan.
The less training data is available, the better the quality of the
data should be. Large training data sets allow for some inaccu-
racies. It is important to keep in mind that training data quality
is a limiting factor for an algorithm’s performance. Therefore,
the required data quality also depends on the envisaged
performance of the algorithm. The decision how to obtain
ground truth again requires both clinical and technical expertise.
It revolves around questions such as how data can be extracted
from hospital information systems, whether or not to use public
databases, and how and by how many experts the ground truth
should be established. Whenever patient data leaves primary
clinical systems, it is of upmost importance to ensure complete
de-identification. In radiology, this includes erasing or overwrit-
ing all DICOM tags that contain data privacy relevant informa-
tion. It is highly recommended to double-check the success of
this de-identification process by reviewing DICOM metadata
before sending image data. An approach that allows for collab-
orative training of an ML model without exchanging data sam-
ples is “Federated learning” [8]: a copy of an algorithm is
downloaded and local data used to further improve it. The
resulting changes to the model are summarized in an update
that is uploaded and merged with the central consensus model.
Preferably, ground truth data is stored in interchangeable for-
mats (e.g., the Neuroimaging Informatics Technology Initiative
(NIfTI) data format for segmentations) to assure usability for
other projects. This is also in accordance with the FAIR guiding
principles for scientific data management and stewardship [9].
Unfortunately, so far no standards have been established for
ML and most clinically used post-processing software is not
capable of exporting segmentation masks, which limits the re-
usability of data and impedes reproducibility of studies.
There are many other types of ground truth labels, com-
prising labels on the level of a whole dataset (fracture on
radiograph: yes/no) and outcome labels for prediction
modeling (patient death: yes/no).
In cardiovascular radiology, most algorithms solve segmenta-
tion tasks; therefore, segmentation masks are the predominant
type of ground truth in this field. However, also tissue character-
ization (e.g., T1 and T2 mapping, late gadolinium enhancement)
is an increasing part of cardiovascular radiology and needs ade-
quate ground truth labels, e.g., histological results from
endomyocardial biopsies in myocarditis. Awareness for potential
Any algorithm that mimics human intelligence
(including, e.g. conventional calculators)
Machine Learning (ML)
Subset of AI algorithms that improve performance
after being exposed to new data without human interference
(including, e.g. support vector machines and random forest) 
Deep Learning (DL)
Subset of ML algorithms consisting 
of multiple calculation layers that 
permit the extraction of
high-level features 
Fig. 1 Relation and definition of artificial intelligence (AI), machine learning (ML), and deep learning (DL)
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biases introduced by the composition of datasets is important: an
algorithm for clinical outcome prediction developed on a training
dataset containing 80% males from country A might not work
well on data from female patients in country B. In general, the
dataset on which an algorithm is developed should reflect the
population on which the algorithm is later applied as good as
possible. Either one is aware of these limitations or overcomes
the challenge by using large, heterogeneous datasets. The gold
standard is to evaluate an algorithm’s performance in clinical
practice and their influence on clinical workflows. Finally, a
suitable ML technique has to be selected (e.g., random forest or
deep convolutional neural networks). This task demands the ex-
pertise of the ML expert. This, as other steps, also involves eth-
ical considerations, e.g., whether it is legitimate to develop algo-
rithms on data of highly developed countries only (resulting in
better performance in these patient collectives). For a detailed
discussion of ethical implications of the use of ML in radiology,
we refer to a recently published multisociety statement [10].
The third step is performance evaluation. There is a wide
range of statistical tests that can be used, beginning with sim-
pler concepts like sensitivity and specificity for detection tasks
to more complex evaluations like the Dice similarity score that
ranges from 0 to 1 and quantifies the overlap of two regions of
interest [11]. The evaluation method should be defined in
advance to avoid method selection bias and involvement of
a statistician is highly recommended. It is the responsibility of
the radiologist to make sure the selected evaluation method
reflects the clinically relevant endpoint. This demands func-
tionality to visually check the validity of the data.
Furthermore, the evaluation has to reflect the intended clinical
use in the specific patient population the algorithm was de-
signed for. It is also important to consider multicenter testing
on different scanner models and patient populations should
the algorithm later be used at other clinical centers and in
different patient populations.
Finally, if assessed as an effective solution to the clin-
ical problem, translation into clinical practice follows.
This last step is at least as challenging as all previous
steps and requires expertise in fields that are rarely cov-
ered by medical and ML experts, namely in user interface
design, graphic design, regulatory matters, and in assuring
compatibility with existing hospital IT environments that
are subject to changes over time and location. While the
creation of a dedicated software package is the most com-
mon option, the gold standard is the direct integration of
algorithm and its output into existing systems, preferably
into Radiology Information Systems/Picture Archiving
and Communication (RIS/PACS) systems and radiology
reports. This results in a smooth workflow, thereby ensur-
ing acceptance and engagement by users.
In our experience, the best results come from a close coop-
eration between experts from different disciplines. Figure 2
summarizes the four-step process.
(b) Hardware and software requirements
Consensus statement
• While some less computationally intensive ML applica-
tions can be run on central processing units (CPUs),
most currently applied ML algorithms require hardware
with dedicated graphics processing units (GPUs).
• Experts involved in ML development should make use of
online resources for creating, sharing, and discussing
ML algorithms.
Besides human expertise, ML projects have requirements
with regard to hardware and software.
Hardware Standard CPUs are sufficient to run most non-DL
ML algorithms and evenDL approaches like deep convolutional
neural networks (DCNNs) with few layers. However, DCNNs
with multiple layers, which constitute the majority of currently
developedML algorithms of interest for cardiovascular imaging,
are more computationally intensive. These algorithms need ded-
icated hardware with GPUs. Commercially available consumer
GPUs with 8 GB or more system memory currently suffice for
many applications. A detailed overview on hardware for ML, its
performance, and pricing is provided by Tim Dettmers [12].
Alternatively, data can be processed using off-site cloud solu-
tions such as Amazon Web Services.
Software The ML community is fully digital and publishes
mostly open source. Practically all relevant resources like soft-
ware libraries and discussion forums are freely accessible.
Jupyter Notebook is a commonly chosen web-based platform
to compile ML algorithms (jupyter.org). The platform allows
the use of multiple programming languages, including
Python, which currently is the most prevalent language in
the field of ML (python.org). A programming language can
be thought of as the vocabulary and rule system that is used to
instruct a computer to perform tasks. ML algorithms can be
developed using software libraries like TensorFlow
(tensorflow.org), scikit-learn (scikit-learn.org), and PyTorch
(pytorch.org). These libraries contain pre-written code and
procedures that enable easier and faster software code devel-
opment. Other alternatives are MATLAB (mathworks.com)
and R (www.r-project.org). Once the code is created, it
should preferably be shared publicly. GitHub is a common
online Git repository for sharing and discussing software
code with version control function that allows to retrace a
project’s source code history (github.com). Furthermore,
anonymization tools are important for ML projects in
radiology, because sensitive patient information is part of the
DICOM header of each image and data exchange is needed to
build large databases with studies from multiple centers.
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Fortunately, there are numerous free stand-alone tools with
b a t c h p r o c e s s i ng f un c t i o n f o r Mac OS ( e . g . ,
dicomanonymizer.com) and Windows (e.g., rubomedical.
com/dicom_anonymizer). The RSNA’s Clinical Trials
Processor (CTP) is open-source software that covers the
whole image transfer pipeline between data acquisition sites
and a principal investigator site with build-in anonymization
capability (mirc.rsna.org). Figure 3 provides an overview of
useful software and online resources.
Recommendations regarding study design
and reporting
Consensus statement
• Based on existing study quality standard frameworks
such as SPIRIT and STARD, we propose a list of quality
criteria for ML studies in radiology.
ML studies should be held to the same quality standards as
any other diagnostic or prognostic study. Several frameworks
exist that define standard protocol items for clinical trials as
well as for reporting the results of diagnostic and prognostic
studies. Clinical trial protocols should conform to the Standard
Protocol Items: Recommendations for Interventional Trials
(SPIRIT) checklist [13]. Diagnostic accuracy studies to the
Standards for Reporting of Diagnostic Accuracy Studies
(STARD) requirements and, at a minimum, should report es-
sential items listed in the 2015 version of the STARD checklist
[14]. For prognostic studies, the Transparent Reporting of
Multivariable Prediction Model for Individual Prognosis or
Diagnosis (TRIPOD) guideline and checklist [15] should be
followed. Although these guidelines were not designed with
ML studies in mind, they do form a solid basis for providing
the details of a ML study in a protocol (SPIRIT), and for
reporting results of studies in which ML has been applied
(STARD and TRIPOD). Because these guidelines have not
been taken up widely in the ML community, efforts are under-
way to develop ML-specific versions of each of these frame-
works. In the meanwhile, we attempt to provide guidance by
offering a checklist of items for researchers designingML stud-
ies and for readers assessing the quality of published reports.
Our efforts expand upon the recently published editorial by
Bluemke et al, which also addresses this topic [16].
Recommended items for designing and reporting ML studies
In the following section, we provide a list of important con-
siderations when designing and reading studies that employ
ML. We have summarized these considerations in a checklist
(Table 1) and apply them to a research article that aimed to
design a DL algorithm for automatic cardiac chamber segmen-
tation and quantification of left ventricular ejection fraction
(LVEF; [17]; Table 2).
1. Which clinical problem is being solved?
A clear description of the clinical problem and rationale for














relevant problem solvable by 
ML techniques
Deep convolutional neural networks 
as established ML method for 
segmentation tasks
Compilation of a representative 
study dataset
Careful selection of hyperparameters










Clinical relevant tasks are:
• frequently performed
• time consuming
• subject to high inter-reader variability
Segmentation tasks are solvable by ML 
as there are plenty of ML algorithms 
for segmentation
Using similarity measures like 
Dice Similarity Coecient as main 
evaluation methods, because both 
location and area are important
Strict separation of a testing dataset
Integration into established systems 
(e.g. RIS/PACS) to ensure:
• seamless integration into existing 
• constant availability;




Fig. 2 Expertise needed during ML algorithm development and implementation, illustrated with the example of a segmentation task
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approaches and how they fall short. This includes the specifi-
cation of the disease in question and a clear description of the
subjects or patients studied. It is also important to hypothesize
how ML approaches may improve upon existing approaches
such as conventional statistical approaches to solve the prob-
lem. Other relevant questions include the stage of the disease
in question and place in the diagnostic pathway.
2. Choice of ML model
The choice of ML model should be clearly motivated since
there is a wide variety of approaches, which may result in dif-
ferent results. It is also important to explicitly discuss overfitting
and approaches used tomitigate this problem. Overfitting occurs
when ML models are trained to predict training data too well,
which results in the inability to generalize to new, unseen data.
An overview of commonly used ML models and their charac-
teristics as well as approaches that can be used to deal with
overfitting is provided by Liu et al in their review article [18].
Technical details of the algorithm including hyperparameters
should be specified to foster transparency and replicability.
3. Sample size motivation
In contrast to the recommendations made in the STARD
and CONSORT guidelines, most ML studies have not explic-
itly considered sample size when designing the study and are
often based on convenience samples. However, sample size
and a statistical analysis plan should ideally be prespecified.
Although there are presently no clear guidelines on how to
calculate a sample size in ML studies, the number of subjects
or datasets can be prespecified according to considerations
such as the minimal clinical difference of interest or the ex-
pectation that ML is able to generate equivalent results to
human observers on a certain task. Furthermore, sample sizes
used by other researchers to solve comparable problemsmight
be a good indicator.
4. Specification of study design and training, validation, and
testing datasets
Algorithm development demands data for training, valida-
tion, and testing. Investigators should specify how the data
was split into each of these categories. It is of utmost impor-
tance to strictly separate the testing dataset from the other
datasets to obtain a realistic estimate of model performance.
This is also a requirement for regulatory approval of ML-
based computer-assisted detection devices from the United
States Food and Drug Administration (FDA) [19]. Ideally,
validation is performed not only on internal data (from the
same department or institute) but also on an external dataset
by independent researchers.
5. Standard of reference
A key consideration in ML studies is selection and quality
of the reference standard or ground truth. Researchers should
precisely specify how and by whom ground truth data were
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Fig. 3 Useful software at different stages of a ML project in radiology
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labeled, including the level of experience of each observer. It
is important to take into account interobserver variability be-
tween experts and to describe how disagreements are resolved
(e.g., by demanding that observers reach a consensus, or by
adjudicating any differences by a separate observer). It should
be noted whether existing labels were used (e.g., from radiol-
ogy reports or electronic health records), or new labels were
created. Finally, experts labeling the data should ideally work
independently from each other because this will facilitate mea-
surement of interobserver agreement between human experts.
6. Reporting of results
Analogous to conventional diagnostic studies, contingency
tables with the number of true positive, true negative, false
positive, and false-negative classifications should be given at
the prespecified chosen classifier threshold. Other useful mea-
sures include the area under the receiver operating curve
(AUC) and Bland-Altman plots [20]. It is important to note
that terminology in ML studies may be different from the
terminology used in the medical literature. Sensitivity is
equivalent to “recall” and “precision” denotes positive predic-
tive value. The F1 score is a compound measure of precision
and recall and its use is therefore highly recommended.
Table 3 summarizes measures frequently used in ML.
Confidence intervals should be reported for all of these mea-
sures. In image segmentation and analysis tasks, measures of
how well the ML algorithm performs compared to the stan-
dard of reference should be given. These typically include the
Dice coefficient (a measure of how well the ML generated
contours overlap with the standard of reference contours),
the mean contour distance (the mean distance between two
segmentation contours), and the Hausdorff distance (the max-
imum distance between the 2 segmentation contours) [11].
7. Are the results explainable?
Because of the large number of parameters involved,
interpreting the results of ML studies can be challenging, es-
pecially when working with DL algorithms. This consider-
ation is particularly pertinent when important treatment deci-
sions are contingent upon the results generated by the algo-
rithm. Saliency mapping enables the identification of morpho-
logical features in the input image underlying the model’s
prediction and can help to investigate the algorithm’s internal
logic. Visual feedback about the model’s predictions is very
important to understand whether networks learn patterns
agreeing with accepted pathophysiological features or biolog-
ically unknown, potentially irrelevant features.
8. Can the results be applied in a clinical setting?
Machine learning studies designed to solve a specific clin-
ical problem should explicitly consider whether the results
apply to a real-world clinical setting. This includes discussion
of how representative the dataset used for derivation and test-
ing of the model is of the clinical setting in which it will be
applied. Any sources of bias, in particular class imbalance and
spectrum bias, should be identified and discussed.
Considering these factors can enable more precise identifica-
tion of patients in which the algorithm can be used clinically,
or in which groups of patients and clinical scenarios additional
validation is needed. Investigators should also consider if and
Table 1 Checklist of items to include when reporting ML studies
1. Which clinical problem is being solved?
□ Which patients or disease does the study concern?
□How canML improve upon existing diagnostic or prognostic approaches?
□ What stage of diagnostic pathway is investigated?
2. Choice of ML model
□ Which ML model is used?
□ Which measures are taken to avoid overfitting?
3. Sample size motivation
□ Is the sample size clearly motivated?
□ Which considerations were used to prespecify a sample size?
□ Is there a statistical analysis plan?
4. Specification of study design and training, validation, and testing datasets
□ Is the study prospective or retrospective?
□ What were the inclusion and exclusion criteria?
□ How many patients were included for training, validation, and testing?
□Was the test dataset kept separate from the training and validation datasets?
□ Was an external dataset used for validation?*
□ Who performed external validation?
5. Standard of reference
□ What was the standard of reference?
□ Were existing labels used, or were labels newly created for the study?
□ How many observers contributed to the standard of reference?
□Were observers blinded to the output of the ML algorithm and to labels of
other observers?
6. Reporting of results
□ Which measures are used to report diagnostic or prognostic accuracy?
□ Which other measures are used to express agreement between the ML
algorithm and the standard of reference?
□ Are contingency tables given?
□ Are confidence estimates given?
7. Are the results explainable?
□ Is it clear how the ML algorithm came to a specific classification or
recommendation?
□ Which strategies were used to investigate the algorithm’s internal logic?
8. Can the results be applied in a clinical setting?
□ Is the dataset representative of the clinical setting in which the model will
be applied?
□ What are significant sources of bias?
□ For which patients can it be used clinically?
□ Can the results be implemented at the point of care?
9. Is the performance reproducible and generalizable?
□ Has reproducibility been studied?
□ Has the ML algorithm been validated externally?
□ Which sources of variation have been studied?
10. Is there any evidence that the model has an effect on patient outcomes?
□ Has an effect on patient outcomes been demonstrated?
11. Is the code available?
□ Is the software code available? Where is it stored?
□ Is the fully trainedMLmodel available or should the algorithm be retrained
with new data?
□ Is there a mechanism to study the algorithms’ results over time?
*Data from another institute or hospital
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how the algorithm can be used at the point of care, including
issues like availability of the algorithm (e.g., on-premise or via
cloud solutions), how fast results are available (e.g., in real-
time or with a delay), and how results are visualized in order to
check the model’s predictions.
9. Is performance reproducible and generalizable?
To date, in most reports on ML, model development, tuning,
and testing have been performed on a convenience sample of
locally available data. Althoughmany of these reports have dem-
onstrated encouraging results, it is important to investigate the
reproducibility of the model and to perform an external valida-
tion, preferably on multiple datasets from other independent in-
stitutes and investigators. External validation is important to
Table 2 Example of applying the checklist to the research article
“Automated cardiovascular magnetic resonance imaging analysis with
fully convolutional networks” by Bai et al [17]
1. Which clinical problem is being solved?
The study by Bai et al is focused on the fully automated determination
of left ventricular ejection fraction (LVEF) and right ventricular
ejection fraction (RVEF) on cardiovascular magnetic resonance
imaging data, without the need for contour drawing by human experts.
Application of ML can reduce the time and human burden of LVEF
determination, which can easily take 10–15 min per subject.
2. Choice of ML model
The investigators used a DL approach with a fully convolutional neural
network architecture consisting of 16 layers. Separate networks were
trained for three commonly acquired anatomical orientations (short
axis as well as vertical and horizontal long axes). Detailed parameters
regarding network training are provided. The most important measure
to look for with regard to overfitting is the use of strictly separate or
“hold out” test dataset (see item 4 below). There was no explicit
mention of any other measures taken to avoid overfitting.
3. Sample size motivation
The DL algorithm was developed using a convenience sample of 4875
subjects participating in the UK Biobank study. No formal sample
size calculation was provided. A clear statistical analysis plan is
provided in the materials and methods section of the paper. The
algorithm was subsequently applied in a study comparing LVEF in
normal versus obese subjects. Each of these groups consisted of
further 867 patients, also selected from the UK Biobank study. Also
for this second study, no formal sample size calculation was provided.
4. Specification of study design and training, validation, and testing
datasets
A random sample of the British population participating in the UK
Biobank study was used. As such, this is a retrospective
cross-sectional analysis focused on understanding variations in the
LVEF in the general population. Detailed inclusion and exclusion
criteria were provided. The number of patients used for training,
validation, and testing was 3975, 300, and 600 for the short axis
segmentation algorithm; 3823, 300, and 600 for the vertical long axis
algorithm; and 3782, 300, and 600 for the horizontal long axis
algorithm. The investigators do not explicitly mentionwhether the test
dataset was kept separate from the development and validation
datasets. The developed algorithms were tested in 1734 additional UK
Biobank participants. No external validation outside the UK Biobank
was performed.
5. Standard of reference
The standard of reference consisted of the manual annotations of
endocardial and epicardial contours in three anatomical orientations
by 8 separate expert annotators. Their level of training and experience
is not explicitly mentioned. The investigators also do not mention the
number of cases annotated by each individual annotator. Three
principal investigators oversaw the annotators, although the
investigators do not explicitly mention what exactly their role was.
Annotators were blinded for output of the machine learning
algorithms.
6. Reporting of results
To assess the accuracy of the algorithms’ segmentations, the Dice
metric, Hausdorff distance, and mean contour distance were
calculated, using manual annotations as the standard of reference. In
addition, the automatically generated LVEF, right ventricular ejection
fraction (RVEF), and the underlying end diastolic and end-systolic
volumes of the left and right ventricles and left ventricular (LV)
myocardial mass were compared to the reference standard.
Table 2 (continued)
7. Are the results explainable?
The ML algorithms’ outputs can be visually assessed when overlaid on
the obtained cardiac MR images, so the end result is easy to verify by
human experts. There was no mention of any experiments to
investigate the algorithms’ internal logic. However, the DL
architecture used in this study has been extensively described by
others.
8. Can the results be applied in a clinical setting?
Because this study concerns a random sample of the British population,
the reported results only apply to this group of subjects. The
investigators did not test the algorithm in a hospital setting. Based on
this study, its accuracy in patients with suspected or known
cardiovascular disease is unknown. Nevertheless, the algorithm is
capable of running in the hospital on relatively standard computer
hardware in combination with a GPU.
9. Is the performance reproducible and generalizable?
Because the UK Biobank contains cardiac MR images from multiple
different scanners and sites, this study provides strong evidence of the
generalizability of the algorithms’ performance across different MR
hardware platforms and MR scanner operators. However, a
standardized image acquisition protocol was used, which does not
necessarily correspond to routine clinical practice. Because the
algorithm was not tested on non-UK Biobank cardiac MR images, we
do not know its performance outside of this domain. Human expert
interobserver variation was assessed by comparing contours drawn
three expert observers. Finally, the automatically generated contours
for 250 randomly selected test subjects were visually assessed by two
experienced image analysts.
10. Is there any evidence that the model has an effect on patient
outcomes?
The investigators focused on development of an algorithm for
automated ventricular ejection fraction measurement. Outcome was
not studied.
11. Is the code available?
The cardiac MR data including the segmentations are available upon
request for health-related research in the public interest. The software
code is available on GitHub. It is unclear if the algorithm needs to be
retrained with new data.
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investigate the robustness of the model to e.g. differences in
image acquisition and reconstruction methods between different
vendors and institutes and differences in referral patterns and
variability in the prevalence of the condition of interest.
Conversely, we also believe it is advisable to validate external
algorithms prior to local use, especially if the algorithms` results
are used for automated analysis with results directly transferred
into clinical reports instead of use as a second reading tool.
10. Is there any evidence that the model has an effect on
patient outcomes?
Although one of the first proofs of concept in the develop-
ment of an ML algorithm is the investigation of its diagnostic
accuracy, investigators and readers should ask themselves the
question whether there is any evidence of an effect on patient
outcomes. This is especially important for algorithms used for
treatment recommendations and detection of unrequested
findings. Ideally, this should be investigated in prospective,
randomized clinical trials, as is the case for conventional in-
terventions. These considerations also help to detect and mit-
igate reasons for missing impact of diagnostically well
performing algorithms on patient outcomes, such as subopti-
mal communication of results.
11. Is the code available?
Transparency regarding an ML model’s design and func-
tion is key to clinical acceptance. Making the computer code
available to other investigators is a major step towards this
goal and is increasingly becoming a condition for obtaining
funding as well as acceptance of studies in high-quality, peer-
reviewed journals. The GitHub platform facilitates free and
rapid dissemination of software code with basic quality
checks. Investigators should state whether the source code of
their algorithm will be made available and under which con-
ditions. If not, specific reasons should be given. Making the
software code available enables other researchers to indepen-
dently investigate whether reported results can be reproduced
and to improve model performance. Furthermore, it enables
the evaluation of a model’s performance over a prolonged
period of time.
Insights of a systematic literature review
on applications of ML in cardiac radiology
To identify articles on the application of ML in cardiac
radiology, a comprehensive search for articles in PubMed
and EMBASE databases was conducted. The search iden-
tified all articles in the English language registered no later
than 31.01.2020 (n = 599 in PubMed; n = 2559 in
EMBASE). Supplement 1 documents the search strings.
Table 3 Performance metrics frequently used in ML
Metric Definition and details
Recall Fraction of true positive (TP) instances among the instances predicted to be positive by an algorithm, including false
positive (FP) instances (synonym for “positive predictive value”)
Recall = TP
TPþFP
Precision Fraction of the instances predicted to be positive by an algorithm among all TP instances, including false negative (FN)
instances (synonym for “sensitivity”)
Precision = TP
TPþFN
Accuracy Fraction of TP and true negatively (TN) predicted instances among all instances.
Accuracy = TPþTN
TPþTNþFPþFN
F1-score Harmonic mean of precision and recall. Ranges from 0 to 1 (meaning perfect precision and recall). Important measure,
because both high precision and recall are needed for high F1 scores.




False-positive findings Negative instances falsely predicted to be positive by an algorithm. Numbers of false-positive findings are very important in
ML, because too many of them render algorithms useless. Investigating the reasons for false-positive findings may help
to develop strategies to avoid them, but requires domain knowledge in the field of application.
ROC curve Receiver operating characteristic curve. Graph illustrating the discriminative ability of a classifier. Sensitivity (Y-axis)
plotted against the false-positive rate (X-axis) for different classification thresholds. The area under the curve (AUC)
measures the 2D area underneath the ROC curve and provides an aggregate measure of performance.
Intersection-Over-Union
(IoU)
Important measure to assess the performance of algorithms for segmentation tasks. Overlap between two regions of interest,








Another important measure in assessing segmentation algorithms. Ranges from 0 to 1, with 1 indicating perfect overlap.
DSC =
2*Area of overlap
Total area of objects
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Figure 4 displays the exact search and review workflow that
included the removal of duplicates (n = 506) with the auto-
function of the literature management software (Mendeley)
and the exclusion of articles that were not on ML in cardiac
radiology by manual screening (n = 2466). In the next step,
the remaining relevant articles (n = 222) were classified in-
to five categories according to the function of the ML ap-
plications: (a) image acquisition and preprocessing, (b) de-
tection, (c) segmentation, (d) diagnosis, (e) prediction, and
(f) other. The relation of those categories is sequential; e.g.,
detection is a prerequisite for segmentation. The studies
were attributed to the most advanced category according
to the purpose of the given algorithm.
At this point, we briefly mention an example per category;
Fig. 5 presents corresponding images: (a) Tatsugami et al used
a DCNN with 10 layers to reduce the image noise of CT
angiography images. The mean image noise was significantly
lower than that of images reconstructed with standard hybrid
iterative reconstruction alone (18.5 ± 2.8 HU vs. 23.0 ± 4.6
HU) [21]. (b) Howard et al developed five neural networks
on 1676 images to detect and identify cardiac pacemakers and
defibrillators on chest radiographs. They report an accuracy of
99.6% and even classified specific model groups of the de-
vices [22]. (c) Romaguera et al used a DCNN to segment the
left ventricle in short-axis cardiac MRI images and found a
Dice score of 0.92, a sensitivity of 0.92, and a specificity of
1.00 [23]. (d) Lessmann et al developed and tested DCNNs for
an automated calcium scoring on 1744 non-ECG-gated CT
scans without contrast. They report an F1 score of 0.89 for
calcium scoring of coronaries on soft kernel reconstructions
[24]. (e) Coenen et al used a neural network with four layers to
predict the hemodynamic relevance of coronary artery steno-
ses from CTA data alone by using the ML-based FFR (frac-
tional flow reserve) with invasively measured FFR as a stan-
dard of reference. They report an improved diagnostic accu-
racy of CTA-based assessment of stenosis from 71 to 85%
(sensitivity: 89%; specificity 76%) [25].
Figure 6 demonstrates the exponentially increasing number
of publications on ML in cardiac radiology since 2013.
Figure 7 shows the distribution of modalities and the ML
techniques that were covered in the research articles, with
MRI being the predominant modality (41.4%) and DL being
the most frequently used ML technique (63.1%).
Supplement 2 provides a detailed literature review on ML
in cardiac radiology highlighting and discussing important
studies in all categories. Supplement 3 contains the complete
reference list of all studies resulting from the literature search
and a table with detailed information on the studies.




• ML algorithms provide opportunities along the whole























Fig. 4 Search and review flow diagram
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Machine learning offers great opportunities in cardiovascular
imaging from the perspective of multiple stakeholders. First and
foremost, from a patient perspective, there are opportunities to
avoid unnecessary imaging. Should imaging be deemed neces-
sary, ML offers opportunities to do so with shorter imaging




a) Acquisition & preprocessing b) Detection
c) Segmentation b) Automated analysis e) Prediction
Fig. 5 Examples of application of ML in cardiac radiology. a Curved
multiplanar reformation of CTAs with multiple plaques and a stent in the
right coronary artery; standard hybrid iterative image reconstruction on
the left, image processed with anML algorithmwith reduced noise on the
right [21]. b Correctly identified Advisa device on a plain radiograph
(left) with the according saliency map (right) that visualizes the neural
networks attention [22]. c Segmentation of the LV on MRI by a DCNN
with automatically detected contours in green color [23]. d Automated
detection and quantification of calcifications on non-contrast CT scans
(red: left anterior descending coronary artery; green: left circumflex
coronary artery; yellow: thoracic aorta) [24]. e ML-based CT fractional
flow reserve predicting obstructive stenosis in the mid left anterior


































Fig. 6 Number of articles on ML in cardiac radiology (Y-axis) published
per year between 2013 and 2019 (X-axis), as resulting from the structured
literature review. Studies published earlier than 2013 and in 01/2020 are




























Fig. 7 a Modalities involved and (b) types of ML approaches used in
studies on ML in cardiac radiology (n = 222)
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acquired, automated post-processing facilitated by ML offers
quicker results compared to current workflows and could reduce
interobserver variation and aid in prioritizing studies with urgent
findings. ML can also be used to extract additional relevant
information from images. Some examples relevant to cardiovas-
cular imaging include extraction of volumes of all cardiac cham-
bers instead of just the LV, more detailed analysis of cardiac
motion patterns, and quantification of the amount of
pericoronary and pericardial fat as well as the amount of liver
fat. When reliable algorithms capable of assigning a diagnosis
become available, this could reduce diagnostic error by serving
as a “second reader.” Finally, ML can aid in automatic extrac-
tion of unrequested but prognostically relevant information. For
example, automated detection or exclusion of pulmonary nod-
ules or abnormalities in other organ systems depicted in the
field-of-view would be useful for radiologists specialized in car-
diovascular imaging. Furthermore, ML algorithms can be used
to create detailed local, national, and international databaseswith
normal values for clinical comparison. This will also enable the
detection of smaller effect sizes and more precise results.
(b) Challenges
Consensus statement
• ML algorithms were initially developed to solve prob-
lems in non-medical domains. Due to peculiarities of
health-related data like high inter-reader variability, dis-
persed data storage, and data privacy issues, ML pro-
jects in radiology are facing specific challenges.
• The medical research community should strive for the
compilation of multicenter datasets that are currently
lacking in the field of cardiovascular imaging.
• Further challenges encompass rare disease and/or ana-
tomical variants and compliance with legal frameworks.
The compilation of high-quality datasets for ML projects in
radiology is hampered by some peculiarities of health-related
data. First, there is the issue of significant inter- and intrareader
variability fostered by the fact that many categories in medicine
are not as distinct as those of everyday objects such as dogs or
cars. Second is the complexity of medical image interpretation.
For example, a small hyperintense streak in late gadolinium
enhancement imaging may be a hyperintensity artifact or a true
scar. For clarification, one needs to integrate additional infor-
mation such as whether there is an implanted cardiac device or
not. Third, there is a lack of standardization in the acquisition of
medical data. In radiology, heterogeneity is introduced by dif-
fering vendors of hardware, software, and unstandardized ac-
quisition parameters. This is true for imaging data, and also for
other diagnostic tests and therefore prevents “one-fits-all” so-
lutions. The fourth challenge concerns the non-standardized
format and dispersed nature of health data. While in other areas
like engineering data is registered in interchangeable systems
often designed from scratch, data in hospitals are mostly stored
in dispersed, historically grown data silos in multiple data for-
mats. The fifth challenge, especially relevant to cardiovascular
radiology, is dealing with higher dimensional imaging data. For
example, cardiac cine images are four-dimensional, while ML
algorithms are traditionally designed to cope with data in two
dimensions. Solutions to this challenge are either complex, or
reduce information (processing of a 3DCT dataset as a series of
multiple 2D images). Another important challenge to ML pro-
jects in radiology is strict standards of data privacy.
All this makes the creation of high-quality ground truth
datasets in healthcare challenging and expensive. As a result,
datasets in healthcare-related ML projects tend to be much
smaller compared to the non-medical domain: the famous
contest for everyday object detection, the ImageNet challenge,
encompasses over 14 million images (http://www.image-net.
org/about-stats), whileML studies in cardiovascular radiology
often comprise less than 100 cases. Public datasets like the
ChestX-ray8 dataset provided by the NIH containing more
than 100,000 frontal-view radiographs with eight disease la-
bels are important initiatives to overcome this problem.
However, labels need critical quality review, which requires
medical domain knowledge. For cardiovascular radiology,
comparable datasets are currently lacking and professional
societies can play an important role in the assembly of large
publicly available datasets with high-quality ground truth la-
bels to allow for an objective comparison of different ML
algorithms. Registries like the ESCR MR/CT registry
(https://www.mrct-registry.org), providing large standardized
data sets for further analyses with currently > 300,000 de-
identified examinations [26], are also an important contribu-
tion in this direction.
Apart from image data–related problems, there are other
challenges. First, there is the problem of rare disease entities.
ML algorithms need a sufficient amount of training examples
to detect patterns, ideally including examples at the extreme
ends of the disease spectrum. However, many radiologic dis-
ease patterns are rarely seen, like congenital heart diseases,
and ensuring a fully representative training dataset remains a
difficulty. Second, legal issues: Machine learning algorithms,
although highly accurate for many tasks, are never perfect and
discussions on legal liability for incorrect or missed diagnoses
are ongoing [27]. Third, the question of acceptance: will phy-
sicians and patients be willing to trust judgments of algorithms
that are a “black box” to them? However, trust in systems not
fully understandable to us is part of day-to-day life.
Conclusion
The number of scientific studies published on ML in cardio-
vascular imaging has been exponentially growing with more
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than 100 research articles in 2019. The majority concerned
MRI studies using DCNNs for image segmentation tasks,
but ML algorithms can also help to shorten imaging protocols
and extract more information from the same imaging data.
The prerequisites for ML to make important contributions in
the field of radiology are now in place: freely available open-
source software, vast amounts of digital radiology data inmost
countries, and an increasing presence of well-trained experts
to train and clinically supervise ML. Furthermore, online
transfer of data and ML models has become convenient.
However, to accomplish this enormous potential, the field
of radiology needs to develop common quality standards re-
garding ML applications and studies. We highlight the need
for a detailed description of datasets and methodology used.
Furthermore, in the course of ML algorithm development that
aims at having a clinical impact, cooperation of professionals
from multiple backgrounds is required.
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